bioAffinity closes private placement of warrants for 980,072 shares at $6.122 exercise price
BIAF•bioAffinity Technologies closed a $4 million registered direct financing priced at $6.122 per share, including pre-funded warrants at $6.115, and a concurrent private placement of warrants covering 980,072 shares at a $6.122 exercise price, subject to stockholder approval.
1. Financing details
The pre-funded warrants have a $0.007 exercise price. The private placement warrants expire five years after stockholder approval. Net proceeds are intended for working capital, supporting expected CyPath Lung sales growth and general corporate purposes.
